KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Total Non-Current Liabilities

Last Annual Value

33.21M

3-Year CAGR

5%

5-Year CAGR

43%

10-Year CAGR

20%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Non-Current Liabilities

KLRS · NASDAQ
CompanyTotal Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
33.21M
-9.2%7.2%N/A 
11.99M
-35.5%N/AN/A
7.88M
-68.6%-49.5%N/A
1.58M
-22.5%-6.5%N/A
0.00
N/AN/AN/A
39.57M
-21.2%-23.3%N/A
86.23M
7.9%-3.3%25.2%
8.51M
-20.3%35.9%N/A
93.61M
-37.9%-20.1%N/A
419.00K
-48.0%-41.7%N/A
12.03M
39.4%20.2%-0.8%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7